Deciphering Current Treatment Recommendations for Type 2 Diabetes
Release Date: August 13, 2015
Last Reviewed: August 7, 2015
Expiration Date: August 13, 2016
Time to Complete Activity: 1.0 hour
Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA
George Grunberger, MD, FACP, FACE
Clinical Professor, Department of Internal Medicine
Clinical Professor, Center for Molecular Medicine and Genetics
Wayne State University School of Medicine
Professor, Department of Internal Medicine
Oakland University William Beaumont School of Medicine
Chairman, Grunberger Diabetes Institute
Bloomfield Hills, MI
Visiting Professor, Department of Internal Medicine
First Faculty of Medicine, Charles University
Prague, Czech Republic
President, American Association of Clinical Endocrinologists
Javier Morales, MD
Associate Clinical Professor of Medicine
North Shore/ LIJ Hofstra School of Medicine
Principal Clinical Trials Investigator
Advanced Internal Medicine Group, PC
Great Neck, NY
Carol H. Wysham, MD, FACP
Clinical Associate Professor of Medicine
University of Washington School of Medicine
Rockwood Center for Diabetes and Endocrinology
This activity is provided by Paradigm Medical Communications, LLC.
This activity has been designed to address the educational needs of physicians specializing in internal medicine, primary care, and endocrinology/diabetology.
Upon proper completion of this activity, participants should be better able to:
- Explain the principles of personalized type 2 diabetes management, including the incorporation of new therapies, as outlined in the most recent clinical guidelines and algorithms.
- Differentiate the efficacy, safety, and tolerability of the incretin-based antihyperglycemic agents so as to appropriately use these agents for individualized type 2 diabetes management.
- Describe the efficacy, safety, and tolerability of SGLT2 inhibitors as well as ongoing outcomes research efforts to appropriately use these agents for individualized type 2 diabetes management.
- Apply guideline and algorithm recommendations to individualize insulin treatment regimens for type 2 diabetes.
- Treatment Plans That Match Individual Agents to Individual Patients: Focus on Incretin-based Therapies
- Where Do SGLT2 Inhibitors Fit Within an Individualized Treatment Plan for the Patient with Type 2 Diabetes?
- Advancing to Triple Therapy, Basal Insulin, and Beyond
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This activity is supported by independent educational grants from AstraZeneca LP and from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the pre-activity assessment
- View the online activity in its entirety.
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
If you have any technical problems or playback issues email us at email@example.com.
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Lawrence Blonde, MD, FACP, FACE (Chair)
Grant/Research Support to Institution: Eli Lilly and Company; Novo Nordisk; sanofi-aventis US
Retained Consultant: AstraZeneca; GlaxoSmithKline; Intarcia Therapeutics, Inc; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; Quest Diagnostics, Inc; sanofi-aventis US
Speakers Bureau: AstraZeneca; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; sanofi-aventis US
George Grunberger, MD, FACP, FACE
Grant/Research Support: AstraZeneca; Eli Lilly and Company; Merck & Co, Inc.; Novo Nordisk; sanofi-aventis US
Speakers Bureau: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc/Eli Lilly and Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; sanofi-aventis US
Javier Morales, MD
Advisory Board: Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Novo Nordisk
Speakers Bureau: Eli Lilly and Company; Novo Nordisk
Carol H. Wysham, MD, FACP
Advisory Board: AstraZeneca; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; sanofi-aventis US
Grant/Research Support: Abbott; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; sanofi-aventis US
Speakers Bureau: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Novo Nordisk; sanofi-aventis US
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Peer reviewer, Carol Levy, MD, CDE, has the following financial relationships to disclose;
Retained Consultant: Janssen Pharmaceuticals, Inc
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities (herein referred to as "website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at firstname.lastname@example.org.
© 2015 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.